Smruthi Organics (BOM:540686) Net Loan

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:540686 Smruthi Organics Ltd BOM:540686
67 GF Score
Price ₹149.40
GF Value ₹124.36
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Smruthi Organics Net Loan?

Net Loan only applies to banks and insurance companies.

BOM:540686
67GF Score
Smruthi Organics Ltd BOM:540686
Net Loan is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Smruthi Organics (BOM:540686) Overvalued in 2026?

Based on GuruFocus' analysis, Smruthi Organics stock appears to be overvalued. The current stock price of ₹149.40 is trading 20.1% above its estimated GF Value™ of ₹124.36. GuruFocus considers Smruthi Organics to be Modestly Overvalued.

Key valuation signals for BOM:540686:

  • Net Loan:
  • GF Value™: ₹124.36 vs. price of ₹149.40 (20.1% above fair value)
  • GF Score™: 67/100 with 6 warning signs

No single metric tells the full story. See the BOM:540686 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Smruthi Organics Business Description

Address Railway Lines, 165-A, 1st Floor, Balaji Bhavan, Solapur, MH, IND, 413001
Smruthi Organics Ltd is engaged in the manufacture of bulk drugs and drug intermediates (API Products). The product portfolio includes Amlodipine Besilate, Amlodipine Base, S-Amlodipine Besilate, S-Amlodipine Base, Norfloxacin, Metformin HCI, Diloxanide Furoate, Phthaloyl Amlodipine, Pantoprazole Sodium, Pefloxacin Mesylate Dihydrate, Telmisartan, Losartan Potassium, and many more. It has two reportable business segments: Bulk Drugs and Drugs Intermediates (API), and Formulation. It generates the majority of its revenue from the Bulk Drugs and Drugs Intermediates (API) segment. Geographically, the company generates maximum revenue from outside India through exports, and the rest from its business within India.
67GF Score

Get the complete analysis for BOM:540686

Net Loan is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹149.40
Price
₹124.36
GF Value